The lawsuit is linked to Emboline’s embolic medical device, which is intended to offer protection from ischemic events.

This is due to the increasing prevalence of CVD and metabolic disorders. The global structural heart devices market, valued ...

The 2024 edition of Transcatheter Cardiovascular Therapeutics (TCT) once again highlighted significant innovations in ...

TTVR also led to "near elimination" of the TR, as 99.1% of people had moderate or less TR (and 95.3% mild or less) at the ...

Israeli heart medical device company Innoventric today announced the completion of a $28.5 million Series B financing round.

The three medtech firms unveiled new data this week during TCT 2024 in Washington, D.C. Here’s what the results mean for the ...

For patients with symptomatic and severe tricuspid regurgitation (TR), tricuspid transcatheter edge-to-edge repair (T-TEER) ...

New analyses bolster the case for tricuspid TEER and reassure on outcomes in patients with implanted electronic devices.

China remains a core market for Edwards Lifesciences, especially with the ongoing improvements in the country's business ...

Routine use of an orbital atherectomy device to remove calcium from severely blocked coronary arteries before patients ...

Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement ... implantation of a right ventricular assist device or heart transplantation, postindex tricuspid-valve ...